13F-HR filed by venBio Partners LLC
venBio Partners LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 7 holding rows worth $276,308,116.
- Accession
- 0000905148-23-000738
- Filer
- CIK 1776382
- Filed
- 2023-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2023
A holdings report, 7 entries on the cover page, a total value of $276,308,116 stated on the cover page (in dollars after the unit check, H1), rows summing to $276,308,116 with VALUE read as dollars as filed, 13F file number 028-19529. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ACELYRIN INC | 00445A100 | COM | 3,857,230 | $80,616,107 | dollars as filed | |
| ALX ONCOLOGY HOLDINGS INC | 00166B105 | COMMON STOCK | 9,699,925 | $72,846,437 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 4,264,672 | $64,567,134 | dollars as filed | |
| HARMONY BIOSCIENCES HLDGS IN | 413197104 | COM | 1,035,396 | $36,435,585 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 424,032 | $13,908,250 | dollars as filed | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 2,914,255 | $4,429,668 | dollars as filed | |
| IMPEL PHARMACEUTICALS INC | 45258K109 | CMN | 2,759,791 | $3,504,935 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000905148-23-000738 | this filing | 2023-08-14 | acceptance time not in the bulk data set |